Tracing New Clinical Manifestations in Patients with COVID-19 in Chile and Its Potential Relationship with the SARS-CoV-2 Divergence

Rodríguez‐Morales, Alfonso J.; Rodriguez-Morales, Andrea G.; Méndez, Claudio A.; Hernández-Botero, Sebastián

doi:10.1007/s40475-020-00205-2

Cited by 29 publications

(34 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Additionally, fever and cough are reported to be the most common symptoms associated with COVID-19 patients [108]. However, mild symptoms like nausea, headache [95], sore throat, myalgia, vomiting and sometimes diarrhoea have also been reported in COVID-19 patients [65,108]. Furthermore, emerging neurological manifestations, such as anosmia and ageusia, have been reported [82].…”

Section: Clinical Pathologymentioning

confidence: 99%

An update on SARS-CoV-2/COVID-19 with particular reference to its clinical pathology, pathogenesis, immunopathology and mitigation strategies

Dhama

Patel

Pathak

et al. 2020

Travel Medicine and Infectious Disease

Self Cite

156

164

View full text Add to dashboard Cite

Coronavirus Disease 2019 (COVID-19), emerged in early December 2019 in China and became a pandemic situation worldwide by its rapid spread to more than 200 countries or territories. Bats are considered as the reservoir host, and the search of a probable intermediate host is still going on. The severe form of the infection is associated with death is mainly reported in older and immune-compromised patients with pre-existing disease history. Death in severe cases is attributed to respiratory failure associated with hyperinflammation. Cytokine storm syndrome associated with inflammation in response to SARS-CoV-2 infection is considered as the leading cause of mortality in COVID-19 patients. COVID-19 patients have thus higher levels of many proinflammatory cytokines and chemokines. The blood laboratory profile of the COVID-19 patients exhibits lymphopenia, leukopenia, thrombocytopenia, and RNAaemia, along with increased levels of aspartate aminotransferase. SARS-CoV-2 infection in pregnant women does not lead to fetus mortality, unlike other zoonotic coronaviruses such as SARS-CoV and MERS-CoV, and there is, to date, no evidence of intrauterine transmission to neonates. Rapid diagnostics have been developed, and significant efforts are being made to develop effective vaccines and therapeutics. In the absence of any virus-specific therapy, internationally, health care authorities are recommending the adoption of effective community mitigation measures to counter and contain this pandemic virus. This paper is an overview of this virus and the disease with a particular focus on SARS-CoV-2/COVID-19 clinical pathology, pathogenesis, and immunopathology, along with recent research developments.

show abstract

Section: Clinical Pathologymentioning

confidence: 99%

An update on SARS-CoV-2/COVID-19 with particular reference to its clinical pathology, pathogenesis, immunopathology and mitigation strategies

Dhama

Patel

Pathak

et al. 2020

Travel Medicine and Infectious Disease

Self Cite

156

164

View full text Add to dashboard Cite

show abstract

“…Although COVID-19 was first described in relation to symptoms of fever, cough, and shortness of breath, it has become apparent that the manifestations of COVID-19 are highly variable and may impact many different organ systems. 4,5,26,27 One element of COVID-19, which may have lasting consequences, is emotional disturbance of affected patients. 18 Diseases that are inherently dangerous or have severe consequences are great sources of depression and anxiety for affected patients and post-convalescent, post-traumatic stress.…”

Section: Association Of Anxiety With Covid-19 Symptom Burdenmentioning

confidence: 99%

Mood, Anxiety and Olfactory Dysfunction in COVID‐19: Evidence of Central Nervous System Involvement?

et al. 2020

View full text Add to dashboard Cite

The objective of this study was to determine the burden of depressed mood and anxiety in COVID-19, and associated disease characteristics. Materials and Methods: This is a prospective, cross-sectional study of 114 COVID-19 positive patients diagnosed using RT-PCR-based testing over a 6-week period. The two-item Patient Health Questionnaire (PHQ-2) and the two-item Generalized Anxiety Disorder questionnaire (GAD-2) were used to measure depressed mood and anxiety level, respectively, at enrollment and for participants' baseline, pre-COVID-19 state. Severity of smell loss, loss of taste, nasal obstruction, rhinorrhea/mucus production, fever, cough, and shortness of breath (SOB) during COVID-19 were assessed. Results: PHQ-2 and GAD-2 significantly (P < .001) increased from baseline to enrollment. PHQ-2 was associated with smell loss (adjusted incidence rate ratio [aIRR]

show abstract

“…Apart from implications of SARS-CoV-2 to have its origin from bats and pangolins and then documented to affect humans leading to mainly respiratory infection and also to cause multiple system infection, the virus infection has also been reported from few animals such as cats, dogs, tiger, lion and mink [24]. Infected patients develop symptoms of high fever, dyspnea, pneumonia, chest pain, dry cough, myalgia and diarrhoea as clinical signs of the disease [25,26] and few other non-respiratory illness symptoms too [27][28][29][30].…”

Section: Annals Of Clinical Microbiology and Antimicrobialsmentioning

confidence: 99%

SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic

Rabaan

Al-Ahmed

Sah

et al. 2020

Ann Clin Microbiol Antimicrob

Self Cite

110

View full text Add to dashboard Cite

A novel coronavirus (SARS-CoV-2), causing an emerging coronavirus disease (COVID-19), first detected in Wuhan City, Hubei Province, China, which has taken a catastrophic turn with high toll rates in China and subsequently spreading across the globe. The rapid spread of this virus to more than 210 countries while affecting more than 25 million people and causing more than 843,000 human deaths, it has resulted in a pandemic situation in the world. The SARS-CoV-2 virus belongs to the genus Betacoronavirus, like MERS-CoV and SARS-CoV, all of which originated in bats. It is highly contagious, causing symptoms like fever, dyspnea, asthenia and pneumonia, thrombocytopenia, and the severely infected patients succumb to the disease. Coronaviruses (CoVs) among all known RNA viruses have the largest genomes ranging from 26 to 32 kb in length. Extensive research has been conducted to understand the molecular basis of the SARS-CoV-2 infection and evolution, develop effective therapeutics, antiviral drugs, and vaccines, and to design rapid and confirmatory viral diagnostics as well as adopt appropriate prevention and control strategies. To date, August 30, 2020, no effective, proven therapeutic antibodies or specific drugs, and vaccines have turned up. In this review article, we describe the underlying molecular organization and phylogenetic analysis of the coronaviruses, including the SARS-CoV-2, and recent advances in diagnosis and vaccine development in brief and focusing mainly on developing potential therapeutic options that can be explored to manage this pandemic virus infection, which would help in valid countering of COVID-19.

show abstract

Tracing New Clinical Manifestations in Patients with COVID-19 in Chile and Its Potential Relationship with the SARS-CoV-2 Divergence

Cited by 29 publications

References 27 publications

An update on SARS-CoV-2/COVID-19 with particular reference to its clinical pathology, pathogenesis, immunopathology and mitigation strategies

An update on SARS-CoV-2/COVID-19 with particular reference to its clinical pathology, pathogenesis, immunopathology and mitigation strategies

Mood, Anxiety and Olfactory Dysfunction in COVID‐19: Evidence of Central Nervous System Involvement?

SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic

Contact Info

Product

Resources

About